×
The submission system is temporarily under maintenance. Please send your manuscripts to
Go to Editorial Manager Objective: The aim of the study is to determine the pharmacological effect of phosphodiesterase 4 inhibitor (dovramilast) in a psoriasis mice model induced by imiquimod, and to estimate the levels of pro-inflammatory cytokines in skin tissue (IL-17A, IL-23 and TNF-α). Furthermore, histopathological scores for skin tissue were determined. Methods: Fifty BALB/c male albino mice aged 8 weeks were used in this study. The mice were classified into five groups each group contain ten mice (n=10) as the following, group I (control) contained healthy mice, group II (induction) involve application of imiquimod 5% cream once daily for five consecutive days to produce inflammatory lesions that resemble to plaque psoriasis, group III, IV and V involve application of imiquimod 5% cream then three hours later treatments were applied for five consecutive days were, group III received clobetasol 0.05% ointment, group IV received dovramilast 0.3% ointment and group V utilize combination of formula contain both dovramilast 0.15% with clobetasol 0.025% ointment. Results: The dovramilast-treated group showed a significant reduction in all inflammatory cytokines (IL-17A, IL-23 and TNF-α) compared to induction (P<0.05) and not significantly differ from clobetasol effect. Furthermore, dovramilast/clobetasol combination providing significant reduction in all measured inflammatory cytokines (P<0.05) when compared to induction and non-significantly differ from clobetasol-treated group. Conclusions: Topical dovramilast, alone or in combination with clobetasol, may represent a promising therapeutic strategy for the management of psoriasis
ABSTRACT Psoriasis (PSO) is an immune-mediated dermatological disorder marked by thick, erythematous, scaly plaques resulting from rapid, excessive cellular growth. Anti-inflammatory agents, immunosuppressant’s, and additional pharmaceuticals serve as the principal therapeutic strategy for psoriasis to alleviate symptoms, diminish inflammation, and inhibit the proliferation and division of epidermal cells. Nevertheless, these drugs generally include disadvantages that impose significant physiological and pathological burdens on patients, including inadequate targeting, brief half-lives, limited absorption rates, and severe toxic side effects. Researchers have recently concentrated significant effort on employing delivery systems for the topical administration of drugs to affected psoriatic skin regions. These systems increase pharmacological efficacy, stability, and penetration. More therapeutic concepts for the treatment of PSO are made possible by the ongoing development of numerous multifunctional topical delivery technologies. This publication reviews various delivery strategies, including hydrogels, nanoparticles, microneedles, micelles, dendrimers, liposomes, nanoemulsions, and vesicles, for topical therapy of PSO and delineates their current developmental status in clinical treatment. It is expected to facilitate the progression of PSO treatment methodologies and provide a benchmark for the development of novel topical delivery systems.
Psoriasis is a chronic immuno-mediated inflammatory disease of 2.3% prevalence in Iraqi the etiology of the disease is not identified well. A wide variation in disease picture and response to treatment occur due to the complexity of the disease. The study includes 75 male and female people diagnosed with psoriasis. General data and treatment used have been analyzed. A questionnaire is prepared. The study shows that there were twenty-one patients aged between 15 and 24 years, thirty-three patients aged between 25 and 34 years, eight patients aged between 35 and 44 years, and thirteen patients were identified as being older than 44 years. The study shows that the distribution of patients is such that fifty-five percent are male, while forty-five percent are female. Betamethasone was most steroid used. Most of the patients repeat the treatment courses more than two times and most of the patients participated in the study use only one drug. In Conclusion both topical and systemic treatment is used and mostly steroids were the common used group.